Leveraging Healthcare System Data to Identify High-Risk Dyslipidemia Patients. [Review]

Leveraging Healthcare System Data to Identify High-Risk Dyslipidemia Patients. [Review] - 2022

PURPOSE OF REVIEW: While randomized controlled trials have historically served as the gold standard for shaping guideline recommendations, real-world data are increasingly being used to inform clinical decision-making. We describe ways in which healthcare systems are generating real-world data related to dyslipidemia and how these data are being leveraged to improve patient care. RECENT FINDINGS: The electronic medical record has emerged as a major source of clinical data, which alongside claims and pharmacy dispending data is enabling healthcare systems the ability to identify care gaps (underdiagnosis and undertreatment) in patients with dyslipidemia. Availability of this data also allows healthcare systems the ability to test and deliver interventions at the point-of-care. Real-world data possess great potential as a complement to randomized controlled trials. Healthcare systems are uniquely positioned to not only define care gaps and areas of opportunity, but to also to leverage tools (e.g., clinical decision support, case identification) aimed at closing them. Copyright © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.


English

1523-3782

10.1007/s11886-022-01767-5 [doi] 10.1007/s11886-022-01767-5 [pii]


IN PROCESS -- NOT YET INDEXED


MedStar Washington Hospital Center


Cardiovascular Disease Fellowship
Internal Medicine Residency
MedStar Georgetown University Hospital/MedStar Washington Hospital Center


Journal Article
Review

Powered by Koha